Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Experts Discuss the Latest Precision Medicine Research

Susan Bernstein  |  Issue: February 2018  |  February 18, 2018

His own interest in genomic medicine dates back 20 years, when he worked on the development of high-resolution genetic mapping of MEFV, the gene mutated in familial Mediterranean fever (FMF) in families of North African and Middle Eastern descent, he said.3

“The idea that you could use tools from the beginning of the Human Genome Project to discover the genes underlying what were, at that time, unexplained conditions, sounded like a really cool thing to do,” said Dr. Kastner. With only a few hundred genetic markers then known, early genomic research required the collection of large amounts of human DNA from donated placentas, he said. “We had to find out what chromosome the gene was on, and we hoped we would eventually find a gene teaching us something about inflammation. That’s exactly what happened. We did find a novel gene, and this protein product nobody knew anything about. There was a long process to figure out what this gene does and how it affects human disease.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

He and his colleagues in the Inter­national FMF Consortium discovered that pyrin, a domain on the MEFV gene, allows molecules in the innate immune system to associate with each other, which led to the discovery of a new signaling pathway. Rho-GTPase, which lives inside the cell membranes of certain leukocytes, normally leads to the activation of PKN-1, a kinase that in turn phosphorylates pyrin and prevents the activation of IL-1, an inflammatory cytokine. Bacterial toxins can inactivate Rho-GTPase and inhibit PKN-1, which then inhibits the phosphorylation of pyrin and leads to the formation of this inflammasome and IL-1 production in these patients, he said.

“So this knowledge has helped us understand this disease better, and has helped us treat patients,” said Dr. Kastner. Some FMF patients don’t respond to colchicine, the usual therapy, because the drug affects Rho-GPTase activity. “For those patients, we now know we can use IL-1 inhibitors. It’s made a huge difference in the lives of those people.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Starting with their discoveries related to MEFV mutations and FMF, Dr. Kastner and other NIH researchers looked at mutations in other genes involved in the same pathway, and they found that several inflammatory diseases, including Muckle-Wells syndrome, familial cold autoinflammatory syndrome and neonatal-onset multisystem inflammatory disease (NOMID), were also related. Although children with NOMID often died before they reached adulthood, genomic research allowed rheumatologists to develop IL-1 inhibitors to treat it, and “now these kids are graduating from high school,” said Dr. Kastner.

Page: 1 2 3 4 5 6 7 8 9 10 | Single Page
Share: 

Filed under:Meeting ReportsRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:ACR/ARHP Annual MeetingArthritisbig dataGenetic researchgenomicsLupusPrecision MedicineRheumatoid arthritis

Related Articles
    Gene Manipulation Has Potential to Alter Genomes, Impact Society

    Gene Manipulation Has Potential to Alter Genomes, Impact Society

    January 19, 2016

    Every so often, a major scientific breakthrough profoundly alters the trajectory of scientific research. In the 1960s, microbiologists sparked the recombinant-DNA revolution with the discovery that bacteria have innate immune systems based on restriction enzymes. These enzymes bind and cut invading viral genomes at specific short sequences, and scientists rapidly repurposed them to cut and…

    Switches That Regulate Gene Expression Offer Better Understanding of Rheumatic Disease Say Experts at the 2013 ACR/ARHP Annual Meeting

    March 1, 2014

    New studies examine why turning on or off switches in genes that control the genome can contribute to pathogenesis of such autoimmune diseases as systemic lupus erythematosus or rheumatoid arthritis

    Genome-Wide Association Studies of SLE

    February 12, 2011

    What do these studies tell us about disease mechanisms in lupus?

    Advances in Precision Immunology Require Precision Controls to Further Research

    October 17, 2017

    CHICAGO—During the 2017 annual Federation of Clinical Immunology Societies (FOCIS) meeting, a session focused on precision immunology and its advances. Precision immunology describes the identification of host, immune system and tumor factors that can be used to select an immunotherapy approach. Thus, the first step in precision immunology is to identify soluble factors, immune cell…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences